Tharimmune announces 1-for-25 reverse stock split

Bridgewater, nj / accesswire / november 17, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock. the reverse stock split was previously approved by tharimmune stockholders at the annual meeting of stockholders held on october 23, 2023, with the final ratio determined by the company's board of directors.
THAR Ratings Summary
THAR Quant Ranking